BofA raised the firm’s price target on Teva to $21 from $18 and keeps a Buy rating on the shares. The firm increased its forecasted sales and EBITDA estimates for Teva in 2025-27 to reflect higher assumed biosimilar contribution based on recent market developments, noting that partner Alvotech guided to b-Humira demand ahead of the firm’s expectations. BofA is increasingly confident the partnership can capture share in 2025-26 launches for Stelera and Simponi, the analyst added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEVA:
Questions or Comments about the article? Write to editor@tipranks.com